Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637382 | 0.86 | KMT2A (0.56) | KMT2AALDH1A1HPGDCYP3A4KDM4E | |
| SCHEMBL30998833 | 0.84 | KMT2A (1.00) | KMT2AALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL6243233 | 0.80 | KMT2A (0.55) | KMT2AALDH1A1HPGDCYP3A4KDM4E | |
| SCHEMBL1944831 | 0.80 | ALDH1A1 (0.63) | KMT2AALDH1A1HPGDCYP3A4KDM4E | |
| SCHEMBL14557584 | 0.79 | ALDH1A1 (0.53) | KMT2AALDH1A1HPGDCYP3A4KDM4E | |
| SCHEMBL6247418 | 0.79 | ALDH1A1 (0.53) | KMT2AALDH1A1HPGDCYP3A4KDM4E | |
| SCHEMBL3797821 | 0.77 | ALDH1A1 (0.59) | KMT2AALDH1A1HPGDCYP3A4KDM4E | |
| SCHEMBL19812546 | 0.77 | ALDH1A1 (0.47) | KMT2AALDH1A1HPGDCYP3A4KDM4E | |
| SCHEMBL14830541 | 0.77 | GRIN1 (0.55) | KMT2A | |
| SCHEMBL220200 | 0.77 | KMT2A (0.57) | KMT2AALDH1A1CYP3A4KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585068-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | disclosed |
| EP-1866290-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-01 | — | — | EP | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R (US) | 2012-09-27 | — | — | US | disclosed |
| US-8188081-B2 | Methods of treating inflammation using prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-8188081-B2 | Methods of treating inflammation using prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-05-29 | — | — | US | disclosed |
| WO-2002064080-A2 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LCC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064599-A1 | BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-0767790-B1 | CONDENSED IMIDAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001029010-A1 | GRAM-POSITIVE SELECTIVE ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| US-5840732-A | ANTIDIABETIC AGENTS, AUTOIMMUNE DISEASES OR IMMUNOSUPPRESSANTS | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0442473-B1 | Pyrimidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-08-19 | — | — | EP | disclosed |
| EP-0767790-A1 | CONDENSED IMIDAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-04-16 | — | — | EP | disclosed |
| WO-1995035296-A1 | CONDENSED IMIDAZOLE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-28 | — | — | WO | disclosed |
| US-5162326-A | Antagonists for angeotensin; hypotensive agents; treatment for heart diseases, strokes | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| EP-0442473-A1 | Pyrimidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | PROKR1, PROKR2, GIPR | KMT2A 4529/4885ALDH1A1 3305/4885HPGD 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.